0001104659-17-048994.txt : 20170802
0001104659-17-048994.hdr.sgml : 20170802
20170802182819
ACCESSION NUMBER: 0001104659-17-048994
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170731
FILED AS OF DATE: 20170802
DATE AS OF CHANGE: 20170802
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lavino Francesco Maria
CENTRAL INDEX KEY: 0001711517
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37558
FILM NUMBER: 171001603
MAIL ADDRESS:
STREET 1: 1000 CONTINENTAL DRIVE
STREET 2: SUITE 600
CITY: KING OF PRUSSIA
STATE: PA
ZIP: 19406
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nabriva Therapeutics plc
CENTRAL INDEX KEY: 0001641640
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 56 FITZWILLIAM SQUARE
CITY: DUBLIN
STATE: L2
ZIP: 2
BUSINESS PHONE: (610) 816-6640
MAIL ADDRESS:
STREET 1: 1000 CONTINENTAL DRIVE
STREET 2: SUITE 600
CITY: KING OF PRUSSIA
STATE: PA
ZIP: 19406
FORMER COMPANY:
FORMER CONFORMED NAME: Nabriva Therapeutics AG
DATE OF NAME CHANGE: 20150507
4
1
a4.xml
4
X0306
4
2017-07-31
0
0001641640
Nabriva Therapeutics plc
NBRV
0001711517
Lavino Francesco Maria
1000 CONTINENTAL DRIVE
SUITE 600
KING OF PRUSSIA
PA
19406
0
1
0
0
Chief Commercial Officer
Stock Option
2017-07-31
4
A
0
150000
0.00
A
2027-07-31
Ordinary Shares
150000
150000
D
The exercise price is Euro 8.94 per share.
This option was granted on July 31, 2017. Vesting will begin on July 31, 2017 and end on July 31, 2021. Twenty-five percent (25%) of the option will vest on July 31, 2018, and the remaining seventy-five percent (75%) will vest on a monthly pro-rata basis over the remaining vesting period.
/s/ Robert Crotty, by power of attorney
2017-08-02